Canakinumab Clinical Trials (2026): 85 Studies for Systemic Juvenile Idiopathic Arthritis & Rheumatoid Arthritis
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
85 Canakinumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 67 indications (including Systemic Juvenile Idiopathic Arthritis & Rheumatoid Arthritis) and 21,677 total planned enrollment. 28 Phase 3 Canakinumab trials and 41 Phase 2, 1 Phase 4 are listed. 6 Canakinumab clinical trials are actively recruiting at 9 U.S. sites across 6 states. Most recent activity: NCT06691217 (Apr 2030).
Where to Participate: All Canakinumab Trial Sites in the U.S. (9 sites across 6 states)
Every actively recruiting Canakinumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| FL | University of Miami | Miami33136 | NCT05641831 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT06691217 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05641831 | Map |
| NY | Weill Cornell Medical College | New York10021 | NCT05641831 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05641831 | Map |
| TN | Vanderbilt University Medical Center | Nashville37232 | NCT05641831 | Map |
| TX | UT Southwestern Medical Center at Dallas | Dallas75235 | NCT05641831 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT04789681 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT04239157 | Map |
Canakinumab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | withdrawn | not yet recruiting | unknown | no longer available | Total |
|---|---|---|---|---|---|---|---|---|---|
| Early P1 | 1 | 1 | |||||||
| P1 | 1 | 1 | 4 | 1 | 7 | ||||
| P1/P2 | 1 | 1 | 1 | 3 | |||||
| P2 | 4 | 3 | 24 | 7 | 1 | 1 | 1 | 41 | |
| P2/P3 | 1 | 1 | 2 | ||||||
| P3 | 1 | 19 | 7 | 1 | 28 | ||||
| P4 | 1 | 1 | |||||||
| N/A | 1 | 1 | 2 |
Recruiting Canakinumab clinical trials (6)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06691217 | TECTONICEffects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis | P2 | Vascular Inflammation | 120 | Mar 2026 |
| NCT05641831 | Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study | P2 | Clonal Cytopenia of Undetermined Significance | 110 | Feb 2023 |
| NCT04789681 | Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial | P2 | Lung Carcinoma | 50 | Jul 2021 |
| NCT07138898 | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty | P2 | Rheumatic Disease | 80 | Sep 2025 |
| NCT04239157 | A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia | P2 | Chronic Myelomonocytic Leukemia | 76 | Aug 2020 |
| NCT05401578 | CanpHyCanakinumab for the Treatment of Postprandial Hypoglycemia | P3 | Postprandial Hypoglycemia | 56 | Apr 2023 |
Canakinumab clinical trials by indication
Systemic Juvenile Idiopathic Arthritis (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02334748 | — | P3 | completed | A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies |
| NCT02396212 | — | P3 | completed | Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA |
| NCT01676948 | β-SPECIFIC 4Pa | P3 | withdrawn | An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) |
| NCT00891046 | β-SPECIFIC 3 | P3 | completed | An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever. |
| NCT00886769 | β-SPECIFIC 1 | P3 | terminated | Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA) |
Rheumatoid Arthritis (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05080218 | COVER | P4 | completed | COVID-19 VaccinE Response in Rheumatology Patients |
| NCT00424346 | — | P2 | completed | Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis |
| NCT00554606 | — | P2 | completed | Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis |
| NCT00487825 | — | P2 | completed | Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis |
Non-small Cell Lung Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04905316 | CHORUS | P2 | active not recruiting | A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer |
| NCT03631199 | CANOPY-1 | P3 | terminated | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects |
| NCT03968419 | CANOPY-N | P2 | terminated | This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. |
| NCT03064854 | — | P1 | terminated | PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients |
Acute Gout (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01080131 | β-RELIEVED-II | P3 | completed | Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study. |
| NCT01029652 | β-RELIEVED | P3 | completed | Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study |
| NCT00798369 | ACZ885 | P2 | completed | Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients |
Myelodysplastic Syndromes (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04798339 | — | P1/P2 | active not recruiting | Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA |
| NCT04810611 | — | P1 | terminated | Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS |
COVID-19 (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04365153 | — | P2 | completed | Canakinumab in Covid-19 Cardiac Injury (The Three C Study) |
| NCT04348448 | — | N/A | terminated | Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia |
Acute Gouty Arthritis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01431638 | — | P3 | completed | Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients |
| NCT01356602 | — | P3 | completed | Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients |
Schnitzler Syndrome (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01390350 | ILESCH | P2 | completed | Ilaris® Effects in Schnitzler Syndrome (ILESCH) |
| NCT01276522 | — | P2 | completed | Efficacy and Safety of Canakinumab in Schnitzler Syndrome |
Gouty Arthritis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01362608 | ACZ885 | P3 | terminated | Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective |
| NCT00927810 | ACZ885 | P2 | completed | Long Term Study of Canakinumab (ACZ885) in Patients With Gout |
Type 2 Diabetes Mellitus (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00605475 | — | P2 | completed | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes |
| NCT01068860 | — | P2 | completed | To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies |
Vascular Inflammation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06691217 | TECTONIC | P2 | recruiting | Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis |
Rheumatic Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07138898 | — | P2 | not yet recruiting | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty |
Cigarette Smoking-Related Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06038526 | — | P2 | active not recruiting | Evaluation of Canakinumab in High-Risk Former-Smokers |
Pancreatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05984602 | — | P1 | active not recruiting | A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer |
Postprandial Hypoglycemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05401578 | CanpHy | P3 | recruiting | Canakinumab for the Treatment of Postprandial Hypoglycemia |
Clonal Cytopenia of Undetermined Significance (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05641831 | — | P2 | recruiting | Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study |
Skin Inflammation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05535738 | — | P2/P3 | active not recruiting | Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation |
Primary Myelofibrosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05467800 | — | P2 | active not recruiting | Study of Canakinumab in Patients With Myelofibrosis |
Anemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05237713 | — | P2 | terminated | Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients |
Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05725343 | CANAL | P3 | terminated | A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer |
Mild Cognitive Impairment (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04795466 | — | P2 | terminated | Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease |
Knee Osteoarthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04814368 | LNA043 | P2 | terminated | A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA) |
Lung Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04789681 | — | P2 | recruiting | Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial |
Adult Onset Still's Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04717635 | — | P3 | completed | Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD |
Metastatic Pancreatic Ductal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04581343 | PanCAN-SR1 | P1 | completed | A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients |
Coronavirus Infection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04510493 | CanCovDia | P3 | completed | Canakinumab in Patients With COVID-19 and Type 2 Diabetes |
Chronic Myelomonocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04239157 | — | P2 | recruiting | A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia |
Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04362813 | CAN-COVID | P3 | completed | Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia |
Metastatic Pancreatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04229004 | — | P3 | completed | A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer |
Carcinoma, Renal Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04028245 | SPARC-1 | Early P1 | completed | A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma |
Duchenne Muscular Dystrophy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03936894 | — | P1/P2 | unknown | Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular Dystrophy |
Alcoholic Hepatitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03775109 | ISAIAH | P2 | completed | IL-1 Signal Inhibition in Alcoholic Hepatitis |
Triple Negative Breast Cancer (TNBC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03742349 | TNBC | P1 | terminated | Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). |
Non-Small-Cell Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03626545 | CANOPY-2 | P3 | terminated | Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy |
Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03447769 | Canopy-A | P3 | terminated | Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A |
Kawasaki Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02980263 | — | P2 | withdrawn | Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease |
Periodic Fevers Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02911857 | — | P3 | completed | An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes |
Periodic Fever (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02775994 | PFAPA | P1 | unknown | Ilaris (Canakinumab) in Patient With Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA) |
Behcet Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02756650 | Behcet | P2 | completed | 1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement |
HIV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02272946 | — | P2 | completed | Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk |
Systemic Juvenile Idiopathic Arthritis (SJIA) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02296424 | ß-SPECIFIC 4 | P3 | completed | ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab |
Hereditary Periodic Fevers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02059291 | — | P3 | completed | Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers |
Atrial Fibrillation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01805960 | CONVERT-AF | P2 | terminated | Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF |
Peripheral Artery Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01731990 | — | P2 | terminated | Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease |
Chronic Idiopathic Urticaria (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01635127 | URTICANA | P2 | unknown | Efficacy Study of Canakinumab to Treat Urticaria |
Adult-Onset Still´s Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02204293 | CONSIDER | P2 | terminated | Canakinumab for Treatment of Adult-onset Still's Disease |
Proliferative Diabetic Retinopathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01589029 | ILARIS | P1 | terminated | A Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP) |
Atherosclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01327846 | CANTOS | P3 | completed | Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) |
Mevalonate Kinase Deficiency (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01303380 | — | P2 | completed | Canakinumab in Patients With Active Hyper-IgD Syndrome |
Pyoderma Gangrenosum (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01302795 | — | P2 | completed | Canakinumab for Pyoderma Gangrenosum |
Colchicine Resistant/Intolerant Familial Mediterranean Fever (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01148797 | CONTROL FMF | P2 | completed | Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF) |
Dry Eye (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01250171 | AIN457 | P2 | completed | The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients |
Type 1 Diabetes (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00947427 | TN14 | P2 | completed | Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes |
Cryopyrin Associated Periodic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01105507 | CAPS | P3 | completed | The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada |
Urticaria (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01170936 | ILUVIT | P2 | completed | Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses |
Familial Mediterranean Fever (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01088880 | — | P2 | completed | Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever |
Osteoarthritis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01160822 | — | P2 | completed | To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee |
Cryopyrin-associated Periodic Syndromes (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00991146 | — | P3 | completed | Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase |
Systemic Juvenile Idiopathic Arthritis With Active Flare (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00889863 | β-SPECIFIC 2 | P3 | completed | Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) |
Diabetes Mellitus, Type 2 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00900146 | — | P2/P3 | terminated | Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients |
NOMID (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00770601 | — | P3 | terminated | Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease |
Gout (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00819585 | — | P2 | completed | A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study) |
Cryopyrin-Associated Periodic Syndromes (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00685373 | — | P3 | completed | Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease |
Arthritis, Gouty (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00663169 | ACZ885 | P2 | completed | Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout |
Chronic Obstructive Pulmonary Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00581945 | ACZ885 | P1/P2 | completed | Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients |
NALP3 Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00487708 | — | P2 | completed | Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms |
Cytokine Release Syndrome in COVID-19-induced Pneumonia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04476706 | — | N/A | no longer available | Canakinumab MAP in COVID-19 Pneumonia With CRS |
Canakinumab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| COVER | NCT05080218 | P4 | completed | Rheumatoid Arthritis | 841 | — |
| CanpHy | NCT05401578 | P3 | recruiting | Postprandial Hypoglycemia | 56 | — |
| CANOPY-1 | NCT03631199 | P3 | terminated | Non-small Cell Lung Cancer | 673 | PMID 38039427 |
| Canopy-A | NCT03447769 | P3 | terminated | Non-Small Cell Lung Cancer | 1,382 | PMID 37788412 |
| CANAL | NCT05725343 | P3 | terminated | Lung Cancer | 350 | — |
| CANOPY-2 | NCT03626545 | P3 | terminated | Non-Small-Cell Lung | 245 | PMID 38354535 |
| CanCovDia | NCT04510493 | P3 | completed | Coronavirus Infection | 116 | PMID 36128334 |
| CAN-COVID | NCT04362813 | P3 | completed | Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia | 454 | PMID 34367680 |
| CANTOS | NCT01327846 | P3 | completed | Atherosclerosis | 10,066 | PMID 37934948 |
| ß-SPECIFIC 4 | NCT02296424 | P3 | completed | Systemic Juvenile Idiopathic Arthritis (SJIA) | 182 | PMID 32783351 |
| ACZ885 | NCT01362608 | P3 | terminated | Gouty Arthritis | 136 | — |
| β-SPECIFIC 4Pa | NCT01676948 | P3 | withdrawn | Systemic Juvenile Idiopathic Arthritis | 0 | — |
| β-SPECIFIC 3 | NCT00891046 | P3 | completed | Systemic Juvenile Idiopathic Arthritis | 270 | PMID 30269054 |
| CAPS | NCT01105507 | P3 | completed | Cryopyrin Associated Periodic Syndrome | 4 | — |
| β-RELIEVED-II | NCT01080131 | P3 | completed | Acute Gout | 226 | PMID 24122883 |
| β-SPECIFIC 2 | NCT00889863 | P3 | completed | Systemic Juvenile Idiopathic Arthritis With Active Flare | 177 | PMID 23252526 |
| β-SPECIFIC 1 | NCT00886769 | P3 | terminated | Systemic Juvenile Idiopathic Arthritis | 84 | PMID 28115015 |
| β-RELIEVED | NCT01029652 | P3 | completed | Acute Gout | 230 | — |
| TECTONIC | NCT06691217 | P2 | recruiting | Vascular Inflammation | 120 | — |
| CHORUS | NCT04905316 | P2 | active not recruiting | Non-small Cell Lung Cancer | 41 | — |
| LNA043 | NCT04814368 | P2 | terminated | Knee Osteoarthritis | 23 | — |
| ISAIAH | NCT03775109 | P2 | completed | Alcoholic Hepatitis | 55 | PMID 34763711 |
| CANOPY-N | NCT03968419 | P2 | terminated | Non-small Cell Lung Cancer | 88 | PMID 33648347 |
| Behcet | NCT02756650 | P2 | completed | Behcet Disease | 8 | — |
| ILESCH | NCT01390350 | P2 | completed | Schnitzler Syndrome | 20 | — |
| CONSIDER | NCT02204293 | P2 | terminated | Adult-Onset Still´s Disease | 36 | PMID 26589963 |
| URTICANA | NCT01635127 | P2 | unknown | Chronic Idiopathic Urticaria | 20 | PMID 32827729 |
| CONVERT-AF | NCT01805960 | P2 | terminated | Atrial Fibrillation | 24 | — |
| TN14 | NCT00947427 | P2 | completed | Type 1 Diabetes | 71 | PMID 23562090 |
| ILUVIT | NCT01170936 | P2 | completed | Urticaria | 10 | — |
| AIN457 | NCT01250171 | P2 | completed | Dry Eye | 72 | — |
| CONTROL FMF | NCT01148797 | P2 | completed | Colchicine Resistant/Intolerant Familial Mediterranean Fever | 15 | PMID 25049046 |
| ACZ885 | NCT00927810 | P2 | completed | Gouty Arthritis | 341 | PMID 21540198 |
| ACZ885 | NCT00663169 | P2 | completed | Arthritis, Gouty | 6 | — |
| ACZ885 | NCT00798369 | P2 | completed | Acute Gout | 200 | PMID 20533546 |
Terminated and withdrawn Canakinumab trials (22)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT03631199terminatedStudy of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects
- NCT04814368terminatedA Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)
- NCT04810611terminatedPhase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS
- NCT04795466terminatedStudy of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease
- NCT05237713terminatedEfficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients
- NCT03447769terminatedBrief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A
- NCT03742349terminatedStudy of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
- NCT05725343terminatedA Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer
- NCT03968419terminatedThis Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.
- NCT03626545terminatedPhase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy
- NCT03064854terminatedPDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
- NCT04348448terminatedObservational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia
- NCT02204293terminatedCanakinumab for Treatment of Adult-onset Still's Disease
- NCT02980263withdrawnStudy of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease
- NCT01805960terminatedCanakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF
- NCT01731990terminatedSafety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease
- NCT01362608terminatedSafety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective
- NCT01676948withdrawnAn Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
- NCT01589029terminatedA Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP)
- NCT00770601terminatedCanakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease
- NCT00886769terminatedSingle-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)
- NCT00900146terminatedDose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients
All Canakinumab trials (85)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06691217 | TECTONIC | Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis | P2 | recruiting | 120 | Massachusetts General Hospital | Mar 2026 |
| NCT05641831 | Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study | P2 | recruiting | 110 | Uma Borate | Feb 2023 | |
| NCT05535738 | Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation | P2/P3 | active not recruiting | 45 | Wei-Che Ko | Nov 2022 | |
| NCT04789681 | Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial | P2 | recruiting | 50 | M.D. Anderson Cancer Center | Jul 2021 | |
| NCT07138898 | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty | P2 | not yet recruiting | 80 | NYU Langone Health | Sep 2025 | |
| NCT05467800 | Study of Canakinumab in Patients With Myelofibrosis | P2 | active not recruiting | 14 | John Mascarenhas | Aug 2022 | |
| NCT04905316 | CHORUS | A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer | P2 | active not recruiting | 41 | Memorial Sloan Kettering Cancer Center | May 2021 |
| NCT04239157 | A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia | P2 | recruiting | 76 | M.D. Anderson Cancer Center | Aug 2020 | |
| NCT06038526 | Evaluation of Canakinumab in High-Risk Former-Smokers | P2 | active not recruiting | 41 | Peter Shields | Mar 2024 | |
| NCT04798339 | Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA | P1/P2 | active not recruiting | 13 | H. Lee Moffitt Cancer Center and Research Institute | Mar 2021 | |
| NCT05984602 | A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer | P1 | active not recruiting | 9 | NYU Langone Health | Jul 2023 | |
| NCT05401578 | CanpHy | Canakinumab for the Treatment of Postprandial Hypoglycemia | P3 | recruiting | 56 | University Hospital, Basel, Switzerland | Apr 2023 |
| NCT04028245 | SPARC-1 | A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma | Early P1 | completed | 17 | Columbia University | Aug 2019 |
| NCT03631199 | CANOPY-1 | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects | P3 | terminated | 673 | Novartis Pharmaceuticals | Dec 2018 |
| NCT04717635 | Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD | P3 | completed | 14 | Novartis Pharmaceuticals | Mar 2021 | |
| NCT04229004 | A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer | P3 | completed | 502 | Pancreatic Cancer Action Network | Jan 2020 | |
| NCT04814368 | LNA043 | A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA) | P2 | terminated | 23 | Novartis Pharmaceuticals | Aug 2021 |
| NCT05080218 | COVER | COVID-19 VaccinE Response in Rheumatology Patients | P4 | completed | 841 | Jeffrey Curtis | Nov 2021 |
| NCT03936894 | Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular Dystrophy | P1/P2 | unknown | 3 | Children's National Research Institute | May 2019 | |
| NCT04810611 | Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS | P1 | terminated | 33 | Novartis Pharmaceuticals | Jun 2021 | |
| NCT04795466 | Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease | P2 | terminated | 34 | Novartis Pharmaceuticals | Oct 2021 | |
| NCT05237713 | Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients | P2 | terminated | 10 | University of Leipzig | Apr 2022 | |
| NCT03775109 | ISAIAH | IL-1 Signal Inhibition in Alcoholic Hepatitis | P2 | completed | 55 | Imperial College London | Feb 2019 |
| NCT04581343 | PanCAN-SR1 | A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients | P1 | completed | 10 | Pancreatic Cancer Action Network | Nov 2020 |
| NCT03447769 | Canopy-A | Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A | P3 | terminated | 1,382 | Novartis Pharmaceuticals | Mar 2018 |
| NCT03742349 | TNBC | Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). | P1 | terminated | 64 | Novartis Pharmaceuticals | Jan 2019 |
| NCT05725343 | CANAL | A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer | P3 | terminated | 350 | Mario Negri Institute for Pharmacological Research | Feb 2022 |
| NCT03968419 | CANOPY-N | This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. | P2 | terminated | 88 | Novartis Pharmaceuticals | Nov 2019 |
| NCT02272946 | Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk | P2 | completed | 43 | Priscilla Hsue, MD | Sep 2015 | |
| NCT03626545 | CANOPY-2 | Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy | P3 | terminated | 245 | Novartis Pharmaceuticals | Jan 2019 |
| NCT04510493 | CanCovDia | Canakinumab in Patients With COVID-19 and Type 2 Diabetes | P3 | completed | 116 | University Hospital, Basel, Switzerland | Oct 2020 |
| NCT03064854 | PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients | P1 | terminated | 111 | Novartis Pharmaceuticals | May 2017 | |
| NCT04365153 | Canakinumab in Covid-19 Cardiac Injury (The Three C Study) | P2 | completed | 45 | The Cleveland Clinic | Apr 2020 | |
| NCT04362813 | CAN-COVID | Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia | P3 | completed | 454 | Novartis Pharmaceuticals | Apr 2020 |
| NCT04348448 | Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia | — | terminated | 100 | AUSL Romagna Rimini | Feb 2020 | |
| NCT04476706 | Canakinumab MAP in COVID-19 Pneumonia With CRS | — | no longer available | 0 | Novartis Pharmaceuticals | — | |
| NCT02775994 | PFAPA | Ilaris (Canakinumab) in Patient With Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA) | P1 | unknown | 10 | Rabin Medical Center | Aug 2016 |
| NCT01327846 | CANTOS | Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) | P3 | completed | 10,066 | Novartis Pharmaceuticals | Apr 2011 |
| NCT02756650 | Behcet | 1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement | P2 | completed | 8 | Novartis Pharmaceuticals | Jun 2016 |
| NCT02334748 | A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies | P3 | completed | 31 | Novartis Pharmaceuticals | Nov 2014 | |
| NCT02396212 | Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA | P3 | completed | 19 | Novartis Pharmaceuticals | May 2015 | |
| NCT01390350 | ILESCH | Ilaris® Effects in Schnitzler Syndrome (ILESCH) | P2 | completed | 20 | Charite University, Berlin, Germany | Jul 2011 |
| NCT02204293 | CONSIDER | Canakinumab for Treatment of Adult-onset Still's Disease | P2 | terminated | 36 | Charite University, Berlin, Germany | Jun 2012 |
| NCT02980263 | Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease | P2 | withdrawn | 0 | Novartis Pharmaceuticals | Nov 2016 | |
| NCT02296424 | ß-SPECIFIC 4 | ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab | P3 | completed | 182 | Novartis Pharmaceuticals | Nov 2014 |
| NCT02059291 | Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers | P3 | completed | 203 | Novartis Pharmaceuticals | Jun 2014 | |
| NCT01635127 | URTICANA | Efficacy Study of Canakinumab to Treat Urticaria | P2 | unknown | 20 | University of Zurich | Jun 2012 |
| NCT02911857 | An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes | P3 | completed | 4 | Novartis Pharmaceuticals | Oct 2016 | |
| NCT01805960 | CONVERT-AF | Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF | P2 | terminated | 24 | University Hospital, Basel, Switzerland | Jun 2013 |
| NCT01731990 | Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease | P2 | terminated | 38 | Novartis Pharmaceuticals | Oct 2012 | |
| NCT01302795 | Canakinumab for Pyoderma Gangrenosum | P2 | completed | 5 | University of Zurich | Feb 2011 | |
| NCT01362608 | ACZ885 | Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective | P3 | terminated | 136 | Novartis Pharmaceuticals | Jun 2011 |
| NCT01676948 | β-SPECIFIC 4Pa | An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) | P3 | withdrawn | 0 | Novartis Pharmaceuticals | Jan 2013 |
| NCT00891046 | β-SPECIFIC 3 | An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever. | P3 | completed | 270 | Novartis Pharmaceuticals | Sep 2009 |
| NCT01589029 | ILARIS | A Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP) | P1 | terminated | 6 | PD Dr. med. Stephan Michels | Apr 2012 |
| NCT01303380 | Canakinumab in Patients With Active Hyper-IgD Syndrome | P2 | completed | 9 | Novartis Pharmaceuticals | Mar 2011 | |
| NCT01431638 | Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients | P3 | completed | 397 | Novartis Pharmaceuticals | Aug 2011 | |
| NCT00947427 | TN14 | Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes | P2 | completed | 71 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Oct 2010 |
| NCT01356602 | Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients | P3 | completed | 397 | Novartis Pharmaceuticals | May 2011 | |
| NCT01105507 | CAPS | The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada | P3 | completed | 4 | Novartis Pharmaceuticals | Aug 2010 |
| NCT00991146 | Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase | P3 | completed | 19 | Novartis Pharmaceuticals | Oct 2009 | |
| NCT01276522 | Efficacy and Safety of Canakinumab in Schnitzler Syndrome | P2 | completed | 8 | Radboud University Medical Center | Jan 2011 | |
| NCT01170936 | ILUVIT | Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses | P2 | completed | 10 | Charite University, Berlin, Germany | Jul 2010 |
| NCT01080131 | β-RELIEVED-II | Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study. | P3 | completed | 226 | Novartis Pharmaceuticals | Mar 2010 |
| NCT01250171 | AIN457 | The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients | P2 | completed | 72 | Novartis Pharmaceuticals | Nov 2010 |
| NCT00889863 | β-SPECIFIC 2 | Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) | P3 | completed | 177 | Novartis Pharmaceuticals | Jul 2009 |
| NCT01088880 | Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever | P2 | completed | 10 | Novartis Pharmaceuticals | Apr 2010 | |
| NCT01160822 | To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee | P2 | completed | 169 | Novartis Pharmaceuticals | Apr 2010 | |
| NCT00770601 | Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease | P3 | terminated | 7 | Novartis Pharmaceuticals | Jan 2009 | |
| NCT00886769 | β-SPECIFIC 1 | Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA) | P3 | terminated | 84 | Novartis Pharmaceuticals | Jul 2009 |
| NCT01148797 | CONTROL FMF | Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF) | P2 | completed | 15 | Novartis Pharmaceuticals | Dec 2010 |
| NCT00900146 | Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients | P2/P3 | terminated | 556 | Novartis | Apr 2009 | |
| NCT01029652 | β-RELIEVED | Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study | P3 | completed | 230 | Novartis Pharmaceuticals | Dec 2009 |
| NCT00605475 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes | P2 | completed | 231 | Novartis | Dec 2007 | |
| NCT01068860 | To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies | P2 | completed | 246 | Novartis | Feb 2010 | |
| NCT00819585 | A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study) | P2 | completed | 432 | Novartis Pharmaceuticals | Dec 2008 | |
| NCT00927810 | ACZ885 | Long Term Study of Canakinumab (ACZ885) in Patients With Gout | P2 | completed | 341 | Novartis Pharmaceuticals | Jun 2009 |
| NCT00581945 | ACZ885 | Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients | P1/P2 | completed | 147 | Novartis | Jan 2007 |
| NCT00685373 | Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease | P3 | completed | 166 | Novartis | May 2008 | |
| NCT00663169 | ACZ885 | Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout | P2 | completed | 6 | Novartis | Apr 2008 |
| NCT00424346 | Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis | P2 | completed | 274 | Novartis | Nov 2006 | |
| NCT00798369 | ACZ885 | Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients | P2 | completed | 200 | Novartis | Nov 2008 |
| NCT00554606 | Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis | P2 | completed | 115 | Novartis | Oct 2007 | |
| NCT00487825 | Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis | P2 | completed | 78 | Novartis | Mar 2007 | |
| NCT00487708 | Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms | P2 | completed | 34 | Novartis Pharmaceuticals | Jan 2005 |
Canakinumab clinical trials: frequently asked questions
- How many Canakinumab clinical trials are there?
- 85 Canakinumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants. 47 are marked completed.
- Are Canakinumab clinical trials recruiting in 2026?
- Yes — 5 Canakinumab trials are actively recruiting in 2026, with 9 U.S. sites across 6 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Canakinumab being studied for?
- Canakinumab is being studied for Systemic Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Non-small Cell Lung Cancer, Acute Gout, Myelodysplastic Syndromes and 102 more. The trials are grouped by indication on this page.
- What phase is Canakinumab in?
- Canakinumab clinical trials span 1 Phase 4, 28 Phase 3, 41 Phase 2, 7 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Canakinumab clinical trials?
- The lead sponsor across the most Canakinumab trials is Novartis Pharmaceuticals, with 27 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Canakinumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: